STAR0602 + Nivolumab for Lung and Prostate Cancers

This trial tests a new cancer treatment called STAR0602, either alone or with an approved drug, nivolumab, to determine if it can enhance the immune system's ability to combat non-small cell lung cancer (NSCLC), metastatic castrate-resistant prostate cancer (mCRPC), and thymic carcinoma (TC). The study will explore different doses to identify the most effective and safest use of these drugs. Individuals with NSCLC, mCRPC, or TC whose cancer has returned or did not respond to previous treatments may qualify for this trial. Participants will receive the drugs through infusions and undergo various health checks throughout the study. As a Phase 1, Phase 2 trial, this research focuses on understanding the treatment's effects in people and measuring its effectiveness in an initial, smaller group.

Research shows that patients generally tolerate nivolumab well. It treats various cancers, and while some side effects occur, they are often manageable. Common side effects include tiredness, skin rash, and joint pain, which are usually mild to moderate.

For STAR0602, less information is available because it remains under testing. The current trial aims to find the best dose, so researchers closely monitor safety. While patients are observed for side effects, the complete safety profile is still being determined.

Researchers are excited about STAR0602 combined with Nivolumab because it offers a novel approach to treating lung and prostate cancers. Unlike traditional treatments like chemotherapy and radiation, which often have broad and harsh effects, STAR0602 targets cancer cells more precisely, potentially reducing side effects. This combination therapy aims to enhance the immune system's ability to fight cancer by using Nivolumab, an immune checkpoint inhibitor, alongside STAR0602, which may have a unique mechanism of action that further boosts the immune response. Additionally, the trial explores both combination therapy and STAR0602 as a standalone treatment, potentially offering flexible options for patients depending on their specific needs.

Research has shown that nivolumab yields promising results for treating certain cancers. Specifically, in patients with non-small cell lung cancer (NSCLC), 60% remained free of cancer recurrence five years after treatment. Nivolumab has also extended patient survival when combined with other NSCLC treatments. In this trial, some participants will receive STAR0602 alone, while others will receive it with nivolumab. Early studies of STAR0602, both alone and with nivolumab, demonstrated a 67% rate of disease control and a 44% rate of tumor reduction. These findings suggest that combining STAR0602 with nivolumab may enhance the body's immune response against these cancers.⁶⁷⁸⁹¹⁰